Viatris Stock Price Closes Higher on April 28 at $9.33, Up 0.76%
May 6, 2023
Trending News 🌥️
Viatris Inc ($NASDAQ:VTRS)., a global healthcare leader in the areas of specialty medicines and complex generics, saw its stock price close higher on April 28 at $9.33, up 0.76% from its previous close. The company is committed to delivering life-changing treatments to patients and supports healthcare systems around the world. With a strong portfolio of products and services, Viatris is well-positioned to continue to provide superior value to its partners and customers.
The positive trend in Viatris Inc.’s stock price reflects the confidence investors have in the company’s long-term prospects. With its expansive global reach, continued commitment to innovation, and dedication to providing quality healthcare solutions, Viatris Inc. is well-positioned to capitalize on growth opportunities in the coming years.
Analysis
At GoodWhale, we have undertaken an analysis of VIATRIS INC‘s financials. Based on our Risk Rating, this is a medium risk investment in terms of financial and business aspects. We have detected two risk warnings in both the income sheet and balance sheet. If you would like to take a closer look, please register on GoodWhale.com for access. We strive to help you make informed decisions by providing reliable and detailed data. With this data, we help you make the right investments with confidence. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Viatris Inc. More…
| Total Revenues | Net Income | Net Margin |
| 16.26k | 2.08k | 13.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Viatris Inc. More…
| Operations | Investing | Financing |
| 2.95k | 1.52k | -3.88k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Viatris Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 50.02k | 28.95k | 17.36 |
Key Ratios Snapshot
Some of the financial key ratios for Viatris Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.2% | 33.6% | 20.9% |
| FCF Margin | ROE | ROA |
| 15.4% | 10.6% | 4.3% |
Peers
The company has a rich history of more than 150 years, dating back to the founding of its predecessor companies, which include some of the world’s most well-known brands. Today, Viatris is a leading provider of essential medicines and solutions, with a presence in more than 150 countries and a workforce of over 30,000 people. The company’s mission is to provide access to high-quality medicines and solutions for patients and customers around the world. Viatris is committed to being a trusted partner for patients, customers, employees, shareholders, and society. The company’s products are available in a wide range of therapeutic areas, including cardiovascular, diabetes, oncology, respiratory, and other conditions. Viatris has a portfolio of more than 1,000 products, including many that are essential medicines. The company also offers a range of services, including manufacturing, distribution, and logistics, to support its customers and patients. Viatris’s competitors include Pfizer Inc, Teva Pharmaceutical Industries Ltd, GSK PLC, and other global pharmaceutical companies.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies. The company was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company’s headquarters are in New York City. The company’s products include medicines and vaccines for a wide range of medical conditions and diseases.
– Teva Pharmaceutical Industries Ltd ($NYSE:TEVA)
Teva Pharmaceutical Industries Ltd is a pharmaceutical company with a market cap of 9.07B as of 2022 and a Return on Equity of -9.35%. The company focuses on producing generic drugs and active pharmaceutical ingredients. Teva is the world’s largest manufacturer of generic drugs and one of the world’s largest pharmaceutical companies.
– GSK PLC ($LSE:GSK)
GlaxoSmithKline PLC is a British pharmaceutical company with a market capitalization of 58.8 billion pounds as of 2022. The company has a return on equity of 34.04%. GlaxoSmithKline is a global healthcare company that researches, develops, and manufactures pharmaceuticals, vaccines, and consumer healthcare products.
Summary
Viatris Inc. has seen an increase in its trading price on April 28th, closing at $9.33. This is a 0.76% increase from its previous close. This could be seen as a positive indicator for investors, as the increase in price suggests that the company is doing well and could potentially be a good investment opportunity.
Analysts suggest keeping an eye on the company’s performance in the coming weeks and months to get a better indication of how it is faring compared to its competitors. It is also recommended to do further research on the company’s financials and operations before investing.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
